Quick Takeaways
- Commodore Capital LP filed SCHEDULE 13G for Karyopharm Therapeutics Inc. Common Stock, $0.0001 par value (KPTI).
- Disclosed ownership: 9.9%.
- Date of event: 26 Mar 2026.
Commodore Capital LP - 26 Mar 2026 SCHEDULE 13G Report for Karyopharm Therapeutics Inc. Common Stock, $0.0001 par value (KPTI)
- Filing Manager
- Commodore Capital LP
- Reporting Manager
- Commodore Capital LP
- Symbol
- KPTI
- Shares outstanding
- 19,696,970 shares
- Disclosed Ownership
- 1,950,000 shares
- Ownership
- 9.9%
- Form type
- SCHEDULE 13G
- Filing time
- 02 Apr 2026, 16:26:26 UTC
- Date of event
- 26 Mar 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Commodore Capital LP disclosed 9.9% ownership in Karyopharm Therapeutics Inc. Common Stock, $0.0001 par value (KPTI) on 26 Mar 2026."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 02 Apr 2026, 16:26.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Commodore Capital LP | 9.9% | 1,950,000 | 0 | 1,950,000 | Michael Kramarz | Managing Partner | |
| Commodore Capital Master LP | 9.9% | 1,950,000 | 0 | 1,950,000 | Michael Kramarz | Authorized Signatory | |
| Robert Egen Atkinson | 9.9% | 1,950,000 | 0 | 1,950,000 | Robert Egen Atkinson | Authorized Signatory | |
| Michael Kramarz | 9.9% | 1,950,000 | 0 | 1,950,000 | Michael Kramarz | Authorized Signatory |